 we report first quarter 2019 net revenues of $5 million which includes net sales of common warts solution for the treatment of common warts or verruca vulgaris and net revenues of common warts solution for the treatment of alopecia aerate and vitiligo. 
 we also report a net loss of $3.7 million for the first quarter of 2019 which includes net net revenue of common warts solution for the treatment of warts or verruca vulgaris for the first time in our history. 
 we also report a net net loss of $3.7 million for common warts solution for the first quarter of 2019. 
 we also report a net loss for common warts solution for the first time in our history for the first quarter of 2019. 
 finally we provide an update on our clinical activities and plans for the remainder of the year.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 